Bioiasis AD (XBUL:BIOA) Notes Receivable: €0.00 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:BIOA Bioiasis AD XBUL:BIOA
12 GF Score
Price €8.25
! 1 Warning Sign
View Full Analysis

What is Bioiasis AD Notes Receivable?

Bioiasis AD XBUL:BIOA 12 Notes Receivable is €0.00 Mil as of Sep. 2025. GuruFocus rates XBUL:BIOA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Bioiasis AD's Notes Receivable for the quarter that ended in Sep. 2025 was €0.00 Mil.

Bioiasis AD Notes Receivable Historical Data

* Premium members only.

The historical data trend for Bioiasis AD's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioiasis AD Notes Receivable Chart

Bioiasis AD Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioiasis AD Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBUL:BIOA
12GF Score
Bioiasis AD XBUL:BIOA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioiasis AD Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Bioiasis AD (XBUL:BIOA) has a Notes Receivable of €0.00 Mil as of Sep. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Bioiasis AD and its competitors.
Is Bioiasis AD's Notes Receivable too high?
Bioiasis AD's current Notes Receivable is €0.00 Mil. Overall, Bioiasis AD has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioiasis AD's Notes Receivable compare to ABT and SYK?
Bioiasis AD's Notes Receivable of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Bioiasis AD and its competitors. Bioiasis AD's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioiasis AD stock overvalued right now?
Bioiasis AD (XBUL:BIOA) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Bioiasis AD's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Bioiasis AD (XBUL:BIOA), the current Notes Receivable is €0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioiasis AD Business Description

Address 60, Deyan Belishki Str., Ground Floor, Sofia, BGR, 1404
Bioiasis AD provides specialized medical devices, equipment, and consultation services to state and private hospitals and trading companies. The company also deals in Interventional Cardiology and General Surgery consumables.
12GF Score

Get the complete analysis for XBUL:BIOA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.25
Price